Gottfried von Keudell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gottfried von Keudell has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Robert Branagan
Massachusetts General Hospital, Boston, Massachusetts, United States
3 shared publications - Gilles Salles
Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications - Jorge J. Castillo
Bing Center for Waldenstrom's Macroglobulinemia Dana‐Farber Cancer Institute Boston MA USA
3 shared publications - Shayna Sarosiek
Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, USA
3 shared publications - Steven Peter Treon
Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 shared publications - Alberto Guijosa
Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA
2 shared publications
Latest Publications
- 15 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1255-1263
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
The BTK inhibitor ibrutinib and the BCL‐2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2‐year fixed‐duration, oral‐based, chemotherapy‐free regimen in symptomatic, treatment‐naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4 (9%) had TP53 alterations. Following enrollment of 45 patients, treatment and enrollment were stopped due to the occurrence of ventricular arrhythmias in 4 (9%), which included two grade 5 events. The median treatment time was 10 cycles, each lasting 28 days. Follow‐up continued after protocol treatment was terminated. The very good partial response/complete response (VGPR/CR) rate was 42%, and it was lower in patients with CXCR4 (29% vs. 50%) or TP53 (25% vs. 44%) mutations. With a median follow‐up of 49 months, the median progression‐free survival (PFS) was 36 months (range 28–42). The median treatment‐free survival (TFS) and overall survival (OS) were not reached, and the 4‐year TFS and OS rates were 73% and 91%, respectively. The median PFS after end of therapy (PFS‐EOT) was 29 months. TP53 mutations were associated with inferior PFS, TFS, and PFS‐EOT, while CXCR4 mutations did not adversely impact these outcomes. Given the deep and durable responses seen in this study, concurrent BTK and BCL‐2 inhibition warrants further development in WM. TP53 mutations emerged as an adverse factor in WM in this combination study.
- 15 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1255-1263
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
The BTK inhibitor ibrutinib and the BCL‐2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2‐year fixed‐duration, oral‐based, chemotherapy‐free regimen in symptomatic, treatment‐naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4 (9%) had TP53 alterations. Following enrollment of 45 patients, treatment and enrollment were stopped due to the occurrence of ventricular arrhythmias in 4 (9%), which included two grade 5 events. The median treatment time was 10 cycles, each lasting 28 days. Follow‐up continued after protocol treatment was terminated. The very good partial response/complete response (VGPR/CR) rate was 42%, and it was lower in patients with CXCR4 (29% vs. 50%) or TP53 (25% vs. 44%) mutations. With a median follow‐up of 49 months, the median progression‐free survival (PFS) was 36 months (range 28–42). The median treatment‐free survival (TFS) and overall survival (OS) were not reached, and the 4‐year TFS and OS rates were 73% and 91%, respectively. The median PFS after end of therapy (PFS‐EOT) was 29 months. TP53 mutations were associated with inferior PFS, TFS, and PFS‐EOT, while CXCR4 mutations did not adversely impact these outcomes. Given the deep and durable responses seen in this study, concurrent BTK and BCL‐2 inhibition warrants further development in WM. TP53 mutations emerged as an adverse factor in WM in this combination study.
- Open Access
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4705-4715
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis
Ibrutinib (I) and ibrutinib plus rituximab (I+R) are highly efficacious in treating Waldenström macroglobulinemia (WM). However, the benefit of adding rituximab remains unclear, and a prospective trial to compare these two regimens has not been undertaken. Therefore, we performed a pooled analysis of prospective studies to compare their effectiveness. Patient-level demographic, response, and survival data were pooled from three prospective studies (ClinicalTrials.gov identifiers: NCT01614821, NCT02604511, NCT02165397). We included patients treated with I+R or I, excluding those without MYD88 mutations. Among 174 patients (58 I+R, 116 I), very good partial response (VGPR) rates were comparable across treatment groups (38% I+R vs 28% I; P = .21). The 48-month progression-free survival (PFS) rate was 74% with I+R vs 61% with I (P = .22). The 48-month overall survival rate was 94% vs 89% (P = .45). In patients with CXCR4 mutations, I+R trended toward higher VGPR (27% vs 11%; P = .10), and had a superior 48-month PFS rate (72% vs 43%; P = .03). CXCR4 mutations were associated with inferior VGPR (42% vs 17%; P = .001) and 48-month PFS in the I arm (43% vs 72%; P = .002). In the I+R arm, CXCR4 mutations were associated with numerically inferior VGPR (47% vs 27%; P = .12), but the 48-month PFS rate was not impacted (74% vs 72%; P = .96). I+R significantly improved PFS over I in patients with CXCR4-mutated WM, along with a nonsignificant increase in VGPR in this subgroup. These results support routine CXCR4 testing in patients with WM, and clinical trials of rituximab with covalent or noncovalent Bruton tyrosine kinase inhibitors.
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4705-4715
Open AccessIbrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis
Ibrutinib (I) and ibrutinib plus rituximab (I+R) are highly efficacious in treating Waldenström macroglobulinemia (WM). However, the benefit of adding rituximab remains unclear, and a prospective trial to compare these two regimens has not been undertaken. Therefore, we performed a pooled analysis of prospective studies to compare their effectiveness. Patient-level demographic, response, and survival data were pooled from three prospective studies (ClinicalTrials.gov identifiers: NCT01614821, NCT02604511, NCT02165397). We included patients treated with I+R or I, excluding those without MYD88 mutations. Among 174 patients (58 I+R, 116 I), very good partial response (VGPR) rates were comparable across treatment groups (38% I+R vs 28% I; P = .21). The 48-month progression-free survival (PFS) rate was 74% with I+R vs 61% with I (P = .22). The 48-month overall survival rate was 94% vs 89% (P = .45). In patients with CXCR4 mutations, I+R trended toward higher VGPR (27% vs 11%; P = .10), and had a superior 48-month PFS rate (72% vs 43%; P = .03). CXCR4 mutations were associated with inferior VGPR (42% vs 17%; P = .001) and 48-month PFS in the I arm (43% vs 72%; P = .002). In the I+R arm, CXCR4 mutations were associated with numerically inferior VGPR (47% vs 27%; P = .12), but the 48-month PFS rate was not impacted (74% vs 72%; P = .96). I+R significantly improved PFS over I in patients with CXCR4-mutated WM, along with a nonsignificant increase in VGPR in this subgroup. These results support routine CXCR4 testing in patients with WM, and clinical trials of rituximab with covalent or noncovalent Bruton tyrosine kinase inhibitors.
- 5 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (Supplement) , 3011
A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
Background: BTK inhibitors and BCL2 antagonists as monotherapy are highly active and well tolerated in Waldenström macroglobulinemia (WM). Non-covalent BTK inhibitors have shown efficacy in WM patients progressing on covalent BTK inhibitors. However, BTK inhibitor therapy has an indefinite duration with cumulative toxicity and risk of developing resistance. We initiated a prospective study evaluating the novel non-covalent BTK inhibitor pirtobrutinib in combination with the BCL2 antagonist venetoclax given as a fixed-duration regimen in previously treated WM. Methods: This was an investigator-initiated, multicenter, prospective phase II study in symptomatic, previously treated WM patients (ClinicalTrials.gov ID NCT05734495). Study therapy was given in 4-week cycles. Intended therapy consists of pirtobrutinib at 200 mg/day on cycle 1. Venetoclax is added on cycle 2 at 100 mg/day for one week, 200 mg/day for one week, and 400 mg/day for two weeks, followed by pirtobrutinib 200 mg/day and venetoclax 400 mg/day given together for cycles 3-24. Patients undergo baseline laboratory studies, a bone marrow biopsy with MYD88, CXCR4, and TP53 genotyping, and CT scans of the chest, abdomen, and pelvis to evaluate extramedullary disease. The outcome of interest was attaining a very good partial response (VGPR) or better. Responses are assessed using modified IWWM6 criteria. Assumptions included H0 15%, H1 35%, 2-sided alpha 0.03, and power 0.85 for a sample size of 42 patients. The null hypothesis will be rejected if 12 or more patients attain a VGPR or better. For this interim analysis, if 3 VGPR or better events or fewer were observed in the first 16 patients, the study should be stopped early because of futility, with a probability of stopping early of 79%. Results: Between May 2023 and June 2024, 16 (8 males; 8 females) patients have been enrolled. Baseline characteristics include median age 67 (range 57-76 years), median number of previous therapies 1 (range 1-3), previous covalent BTK inhibitor 9 (56%), previous rituximab-containing regimens 11 (69%), median serum IgM 2,401 (range 551-7,249 mg/dL), median hemoglobin 8.6 (range 6.6-11.5 g/dL), median bone marrow involvement 80% (20-90%), lymphadenopathy (>1.5 cm) 7 (44%), and splenomegaly (>15 cm) 2 (13%). MYD88 L265P was detected in 14 patients (88%), CXCR4 mutations in 6 (38%), and TP53 mutations in 1 (6%). The median study follow-up is 6 months (range 3-12). VGPR was attained in 9 patients (56%), partial response in 5 (31%), and minor response in 2 (13%), for an overall response rate of 100%. No complete responses were observed. CXCR4 mutations (33% v 70%; p=0.35) and previous exposure to covalent BTK inhibitors (33% v 86%; p=0.05) might be associated with lower VGPR rates. The median time to VGPR was 1.9 months (95% CI 0.9-2.2). CXCR4 mutations (p=0.32) and previous exposure to covalent BTK inhibitors (p=0.50) did not seem to impact time to VGPR. At best response, median serum IgM decreased to 254 (range 35-3786 mg/dl; p<0.001), median hemoglobin increased to 12.1 (range 8.2-16.2 g/dl); p<0.001), and median bone marrow involvement decreased to 0% (range 0-40%; p<0.001) when compared to baseline. Of the seven patients with lymphadenopathy, 5 (71%) had improvement or resolution, and of the two patients with splenomegaly, 2 (100%) had improvement or resolution. Two patients had disease progression at two and five months; both had MYD88 WT disease. The 6-month progression-free survival rate is 84% (95% CI 49-96%), and the 6-month overall survival rate is 93% (95% CI 61-99). There have been no arrhythmia events thus far. Conclusion: The combination of pirtobrutinib and venetoclax appears active in symptomatic, previously treated WM patients with a VGPR rate of 56%, exceeding the futility rate. CXCR4 mutations and previous exposure to covalent BTK inhibitors might impact VGPR rates. Accrual will continue to enroll 26 additional patients.
- 5 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (Supplement) , 3011
A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
Background: BTK inhibitors and BCL2 antagonists as monotherapy are highly active and well tolerated in Waldenström macroglobulinemia (WM). Non-covalent BTK inhibitors have shown efficacy in WM patients progressing on covalent BTK inhibitors. However, BTK inhibitor therapy has an indefinite duration with cumulative toxicity and risk of developing resistance. We initiated a prospective study evaluating the novel non-covalent BTK inhibitor pirtobrutinib in combination with the BCL2 antagonist venetoclax given as a fixed-duration regimen in previously treated WM. Methods: This was an investigator-initiated, multicenter, prospective phase II study in symptomatic, previously treated WM patients (ClinicalTrials.gov ID NCT05734495). Study therapy was given in 4-week cycles. Intended therapy consists of pirtobrutinib at 200 mg/day on cycle 1. Venetoclax is added on cycle 2 at 100 mg/day for one week, 200 mg/day for one week, and 400 mg/day for two weeks, followed by pirtobrutinib 200 mg/day and venetoclax 400 mg/day given together for cycles 3-24. Patients undergo baseline laboratory studies, a bone marrow biopsy with MYD88, CXCR4, and TP53 genotyping, and CT scans of the chest, abdomen, and pelvis to evaluate extramedullary disease. The outcome of interest was attaining a very good partial response (VGPR) or better. Responses are assessed using modified IWWM6 criteria. Assumptions included H0 15%, H1 35%, 2-sided alpha 0.03, and power 0.85 for a sample size of 42 patients. The null hypothesis will be rejected if 12 or more patients attain a VGPR or better. For this interim analysis, if 3 VGPR or better events or fewer were observed in the first 16 patients, the study should be stopped early because of futility, with a probability of stopping early of 79%. Results: Between May 2023 and June 2024, 16 (8 males; 8 females) patients have been enrolled. Baseline characteristics include median age 67 (range 57-76 years), median number of previous therapies 1 (range 1-3), previous covalent BTK inhibitor 9 (56%), previous rituximab-containing regimens 11 (69%), median serum IgM 2,401 (range 551-7,249 mg/dL), median hemoglobin 8.6 (range 6.6-11.5 g/dL), median bone marrow involvement 80% (20-90%), lymphadenopathy (>1.5 cm) 7 (44%), and splenomegaly (>15 cm) 2 (13%). MYD88 L265P was detected in 14 patients (88%), CXCR4 mutations in 6 (38%), and TP53 mutations in 1 (6%). The median study follow-up is 6 months (range 3-12). VGPR was attained in 9 patients (56%), partial response in 5 (31%), and minor response in 2 (13%), for an overall response rate of 100%. No complete responses were observed. CXCR4 mutations (33% v 70%; p=0.35) and previous exposure to covalent BTK inhibitors (33% v 86%; p=0.05) might be associated with lower VGPR rates. The median time to VGPR was 1.9 months (95% CI 0.9-2.2). CXCR4 mutations (p=0.32) and previous exposure to covalent BTK inhibitors (p=0.50) did not seem to impact time to VGPR. At best response, median serum IgM decreased to 254 (range 35-3786 mg/dl; p<0.001), median hemoglobin increased to 12.1 (range 8.2-16.2 g/dl); p<0.001), and median bone marrow involvement decreased to 0% (range 0-40%; p<0.001) when compared to baseline. Of the seven patients with lymphadenopathy, 5 (71%) had improvement or resolution, and of the two patients with splenomegaly, 2 (100%) had improvement or resolution. Two patients had disease progression at two and five months; both had MYD88 WT disease. The 6-month progression-free survival rate is 84% (95% CI 49-96%), and the 6-month overall survival rate is 93% (95% CI 61-99). There have been no arrhythmia events thus far. Conclusion: The combination of pirtobrutinib and venetoclax appears active in symptomatic, previously treated WM patients with a VGPR rate of 56%, exceeding the futility rate. CXCR4 mutations and previous exposure to covalent BTK inhibitors might impact VGPR rates. Accrual will continue to enroll 26 additional patients.
- Open Access
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Recent prospective clinical trial data suggest that patients with Hodgkin’s lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We describe the outcomes of PET2+ patients who continued ABVD and compare the performance of a quantitative measure based on the lesion-to-liver SUV ratio (LLS qPET2+) to that of the subjective Deauville criteria (dvPET2+). We analyzed all patients with newly diagnosed advanced-stage Hodgkin lymphoma treated with frontline ABVD at the Memorial Sloan Kettering Cancer Center between 2008 and 2017. Eligibility was set to correspond with the RATHL inclusion criteria. Images were reviewed by two nuclear medicine physicians and discordant cases were resolved with a third expert in consensus. qPET2+ was defined as LLS ≥ 1.3. We identified 227 patients of whom 25% (57) were qPET2+, but only 14% (31) were dvPET2+. Forty-eight patients (84%) continued ABVD with a 3-year PFS of 70% for qPET2+ and 64% for dvPET2+. In conclusion, interim PET interpretation in clinical practice may be associated with a higher rate of scans deemed positive. Irrespective of the criteria for PET2 positivity, a subset of patients may continue ABVD without a dismal outcome.
Open AccessOutcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Recent prospective clinical trial data suggest that patients with Hodgkin’s lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We describe the outcomes of PET2+ patients who continued ABVD and compare the performance of a quantitative measure based on the lesion-to-liver SUV ratio (LLS qPET2+) to that of the subjective Deauville criteria (dvPET2+). We analyzed all patients with newly diagnosed advanced-stage Hodgkin lymphoma treated with frontline ABVD at the Memorial Sloan Kettering Cancer Center between 2008 and 2017. Eligibility was set to correspond with the RATHL inclusion criteria. Images were reviewed by two nuclear medicine physicians and discordant cases were resolved with a third expert in consensus. qPET2+ was defined as LLS ≥ 1.3. We identified 227 patients of whom 25% (57) were qPET2+, but only 14% (31) were dvPET2+. Forty-eight patients (84%) continued ABVD with a 3-year PFS of 70% for qPET2+ and 64% for dvPET2+. In conclusion, interim PET interpretation in clinical practice may be associated with a higher rate of scans deemed positive. Irrespective of the criteria for PET2 positivity, a subset of patients may continue ABVD without a dismal outcome.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 56
Abstract 56: MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma
Next-generation sequencing of cell-free DNA (cfDNA) can be used to noninvasively assess and monitor patients with lymphoma. Here, we describe the preliminary validation of MSK-ACCESS Heme (Memorial Sloan Kettering-Analysis of Circulating cfDNA to Examine Somatic Status), a cfDNA assay that employs unique molecular indexing and ultra-deep sequencing to detect somatic alterations in 117 genes related to hematologic malignancies. To our knowledge, this is the first report of a clinical-grade cfDNA assay developed specifically for hematologic malignancies. Overall assay performance was assessed using 53 validation samples (26 normal samples and 27 cfDNA samples with somatic variants). Initial accuracy studies showed excellent correlation with the reference next-generation sequencing method (MSK-ACCESS Solid), detecting 32/32 (100%) of expected variants with a variant allele frequency over 1%. The limit of detection was assessed using standard samples, with detection of variants down to 0.5% variant allele frequency. Results were highly concordant in both inter- and intra-assay reproducibility studies. Overall, these data indicate that MSK-ACCESS Heme is a robust cfDNA-based assay that can be used to detect variants at low frequency with high reproducibility. Future work sequencing additional samples will be performed to further assess the performance of the panel. Citation Format: Sara E. DiNapoli, Coleman Spence, Erika Gedvilaite, Anita Bowman, Monica Diosdado, Anna Razumova, Dana Tsui, Gilles A. Salles, Connie Batlevi, Gottfried von Keudell, Ryan Ptashkin, Ahmet Zehir, Michael Berger, A Rose Brannon, Ryma Benayed, Maria Arcila. MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 56.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 56
Open AccessAbstract 56: MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma
Next-generation sequencing of cell-free DNA (cfDNA) can be used to noninvasively assess and monitor patients with lymphoma. Here, we describe the preliminary validation of MSK-ACCESS Heme (Memorial Sloan Kettering-Analysis of Circulating cfDNA to Examine Somatic Status), a cfDNA assay that employs unique molecular indexing and ultra-deep sequencing to detect somatic alterations in 117 genes related to hematologic malignancies. To our knowledge, this is the first report of a clinical-grade cfDNA assay developed specifically for hematologic malignancies. Overall assay performance was assessed using 53 validation samples (26 normal samples and 27 cfDNA samples with somatic variants). Initial accuracy studies showed excellent correlation with the reference next-generation sequencing method (MSK-ACCESS Solid), detecting 32/32 (100%) of expected variants with a variant allele frequency over 1%. The limit of detection was assessed using standard samples, with detection of variants down to 0.5% variant allele frequency. Results were highly concordant in both inter- and intra-assay reproducibility studies. Overall, these data indicate that MSK-ACCESS Heme is a robust cfDNA-based assay that can be used to detect variants at low frequency with high reproducibility. Future work sequencing additional samples will be performed to further assess the performance of the panel. Citation Format: Sara E. DiNapoli, Coleman Spence, Erika Gedvilaite, Anita Bowman, Monica Diosdado, Anna Razumova, Dana Tsui, Gilles A. Salles, Connie Batlevi, Gottfried von Keudell, Ryan Ptashkin, Ahmet Zehir, Michael Berger, A Rose Brannon, Ryma Benayed, Maria Arcila. MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 56.
- Top Cited Papers
- 1 October 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (28) , 3109-3117
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550 ). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2, days 1 and 8), given on 21-day cycles. The primary end point was complete response (CR) following up to four cycles of pembro-GVD. Patients who achieved CR by labeled fluorodeoxyglucose-positron emission tomography (Deauville ≤ 3) after two or four cycles proceeded to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). HDT/AHCT was carried out according to institutional standards, and brentuximab vedotin maintenance was allowed following HDT/AHCT. RESULTS: Of 39 patients enrolled, 41% had primary ref disease and 38% relapsed within 1 year of frontline treatment. 31 patients received two cycles of pembro-GVD, and eight received four cycles. Most adverse events were grade 1 or two, whereas few were grade 3 and included transaminitis (n = 4), neutropenia (n = 4), mucositis (n = 2), thyroiditis (n = 1), and rash (n = 1). Of 38 evaluable patients, overall and CR rates after pembro-GVD were 100% and 95%, respectively. Thirty-six (95%) patients proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance. All 36 transplanted patients are in remission at a median post-transplant follow-up of 13.5 months (range: 2.66-27.06 months). CONCLUSION: Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.
- 1 October 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (28) , 3109-3117
Top Cited PapersPhase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550 ). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2, days 1 and 8), given on 21-day cycles. The primary end point was complete response (CR) following up to four cycles of pembro-GVD. Patients who achieved CR by labeled fluorodeoxyglucose-positron emission tomography (Deauville ≤ 3) after two or four cycles proceeded to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). HDT/AHCT was carried out according to institutional standards, and brentuximab vedotin maintenance was allowed following HDT/AHCT. RESULTS: Of 39 patients enrolled, 41% had primary ref disease and 38% relapsed within 1 year of frontline treatment. 31 patients received two cycles of pembro-GVD, and eight received four cycles. Most adverse events were grade 1 or two, whereas few were grade 3 and included transaminitis (n = 4), neutropenia (n = 4), mucositis (n = 2), thyroiditis (n = 1), and rash (n = 1). Of 38 evaluable patients, overall and CR rates after pembro-GVD were 100% and 95%, respectively. Thirty-six (95%) patients proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance. All 36 transplanted patients are in remission at a median post-transplant follow-up of 13.5 months (range: 2.66-27.06 months). CONCLUSION: Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.
- Open Access
Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential
Although chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) using formalin-fixed paraffin-embedded tissue (FFPE) has been reported, it remained elusive whether they retained accurate transcription factor binding. Here, we developed a method to identify the binding sites of the insulator transcription factor CTCF and the genome-wide distribution of histone modifications involved in transcriptional activation. Importantly, we provide evidence that the ChIP-seq datasets obtained from FFPE samples are similar to or even better than the data for corresponding fresh-frozen samples, indicating that FFPE samples are compatible with ChIP-seq analysis. H3K27ac ChIP-seq analyses of 69 FFPE samples using a dual-arm robot revealed that driver mutations in EGFR were distinguishable from pan-negative cases and were relatively homogeneous as a group in lung adenocarcinomas. Thus, our results demonstrate that FFPE samples are an important source for epigenomic research, enabling the study of histone modifications, nuclear chromatin structure, and clinical data.
Open AccessGenome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential
Although chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) using formalin-fixed paraffin-embedded tissue (FFPE) has been reported, it remained elusive whether they retained accurate transcription factor binding. Here, we developed a method to identify the binding sites of the insulator transcription factor CTCF and the genome-wide distribution of histone modifications involved in transcriptional activation. Importantly, we provide evidence that the ChIP-seq datasets obtained from FFPE samples are similar to or even better than the data for corresponding fresh-frozen samples, indicating that FFPE samples are compatible with ChIP-seq analysis. H3K27ac ChIP-seq analyses of 69 FFPE samples using a dual-arm robot revealed that driver mutations in EGFR were distinguishable from pan-negative cases and were relatively homogeneous as a group in lung adenocarcinomas. Thus, our results demonstrate that FFPE samples are an important source for epigenomic research, enabling the study of histone modifications, nuclear chromatin structure, and clinical data.
- 11 December 2018
- Published by Wiley in British Journal of Haematology
- Vol. 184 (1) , 105-112
Novel therapeutic agents for relapsed classical Hodgkin lymphoma
Summary: Hodgkin Lymphoma (HL) is a B‐cell lymphoproliferative disorder with an excellent prognosis for the majority of patients who are treated with multi‐agent chemotherapy, with or without radiation. A subset of patient, however, does not respond to therapy or relapses after accomplishing an initial response. Their outcome is poor and new treatment strategies are urgently needed for this patient population. Recent advances in the understanding of the tumour biology of HL and its microenvironment have ushered a new era of targeted‐ and immuno‐therapies with remarkable activity. Most notably, the antibody‐drug conjugate brentuximab‐vedotin, and the immune checkpoint blockers pembrolizumab and nivolumab have recently been approved by the US Food and Drug Administration and have transformed the therapeutic landscape of this disease. Other novel drug compounds are being investigated either as single agents or in combination and hold promise to further the field.
- 11 December 2018
- Published by Wiley in British Journal of Haematology
- Vol. 184 (1) , 105-112
Novel therapeutic agents for relapsed classical Hodgkin lymphoma
Summary: Hodgkin Lymphoma (HL) is a B‐cell lymphoproliferative disorder with an excellent prognosis for the majority of patients who are treated with multi‐agent chemotherapy, with or without radiation. A subset of patient, however, does not respond to therapy or relapses after accomplishing an initial response. Their outcome is poor and new treatment strategies are urgently needed for this patient population. Recent advances in the understanding of the tumour biology of HL and its microenvironment have ushered a new era of targeted‐ and immuno‐therapies with remarkable activity. Most notably, the antibody‐drug conjugate brentuximab‐vedotin, and the immune checkpoint blockers pembrolizumab and nivolumab have recently been approved by the US Food and Drug Administration and have transformed the therapeutic landscape of this disease. Other novel drug compounds are being investigated either as single agents or in combination and hold promise to further the field.